Logo

AbbVie's Mavyret (glecaprevir/pibrentasvir) Receives FDA's Approval for its Expanded Indication in Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis Across All Genot

Share this

AbbVie's Mavyret (glecaprevir/pibrentasvir) Receives FDA's Approval for its Expanded Indication in Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis Across All Genot

Shots:

  • The US FDA has granted approval to Mavyret for shortening the treatment duration from 12 to 8wks. in treatment-naïve- compensated cirrhotic- chronic hepatitis C (HCV) patients across all genotypes (GT1-6)
  • The label expansion is based on P-IIIb EXPEDITION-8 study assessing Mavyret in treatment naïve- GT1-6 chronic HCV patients with compensated cirrhosis for 8wks.- resulted in achieving sustained virologic response 12 weeks (SVR12) in 98% patients
  • Mavyret (qd) is a pan-genotypic- combination of glecaprevir (100mg) and pibrentasvir (40mg) and has received FDA’s approval as an 8-week- pan-genotypic treatment for the treatment-naïve HCV patients without cirrhosis in Aug’2017

Click here to­ read full press release/ article 

 Ref: AbbVie | Image : AbbVie


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions